Biocorp announces the signature of an agreement for the sale by its main shareholder BIO JAG of 1,998,800 shares (representing 45.3% of the capital and 62.2% of the voting rights), at a price of 35 euros per share, to Novo Nordisk.

Completion of the acquisition of this controlling block and of the shares held by minority shareholders, together representing 64.4% of the capital and 75.3% of the voting rights, is subject to obtaining the usual regulatory approvals.

As a result of the proposed transaction, Novo Nordisk will file a simplified tender offer with the AMF in the third quarter of 2023, at a price that would value 100% of Biocorp at €154.4 million.

Copyright (c) 2023 CercleFinance.com. All rights reserved.